Press Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
1/13/2020
8:15 AM ET
Press Release

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

1/13/2020

FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous...

 Continue Reading
11/20/2019
9:20 AM ET
Press Release

Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

11/20/2019

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of...

 Continue Reading
11/19/2019
4:01 PM ET
Press Release

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

11/19/2019

NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is prop...

 Continue Reading
11/8/2019
7:30 AM ET
Press Release

Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

11/8/2019

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmaco...

 Continue Reading
11/7/2019
4:30 PM ET
Earnings Release

Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

11/7/2019

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial resu...

 Continue Reading
Displaying 1 to 5 (of 57 releases)